Bioxytran, Inc.
BIXT · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.66 | -0.00 | -0.21 |
| FCF Yield | -0.42% | -1.03% | -13,349.62% | 0.26% |
| EV / EBITDA | -14.43 | 127.85 | -0.95 | -28.01 |
| Quality | ||||
| ROIC | 24.20% | 17.37% | 35.59% | 69.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.15 | -2.28 | 0.12 | -0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | 310,146.08% |
| Free Cash Flow Growth | 72.55% | 42.72% | -623.18% | 51.22% |
| Safety | ||||
| Net Debt / EBITDA | -1.69 | 16.11 | -0.95 | -2.25 |
| Interest Coverage | 13.58 | -4.94 | -16.15 | -0.75 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -24,705.05 | -27,397.49 | -6.39 |